Biotechnology company GigaGen is working on a recombinant polyclonal antibody, recombinant anti-coronavirus 19 hyperimmune gammaglobulin (rCIG), as a Covid-19 treatment.
The therapy reproduces whole antibody repertoires of recovered patients, including antibodies that block further replication of the novel coronavirus.
GigaGen will formulate the antibody for intravenous administration to deliver passive immunity. RCIG does not require a constant supply of plasma from recovered donors, on contrary to plasma-based polyclonal antibodies including convalescent serum therapies, noted GigaGen.
The company’s single-cell technology allows capture and recreation of complete antibodies libraries from convalescent Covid-19 patients.